A provisional evaluation of Australia's medical cannabis program

Dados Bibliográficos

ID14909427
AutoresMyfanwy Graham (0000-0003-0618-7497, University of Southern California, autor correspondente), Vivian Chiu (0000-0002-8729-3330, The University of Queensland), Daniel Stjepanović (0000-0003-4307-423X, The University of Queensland), Wendy Hall (0000-0003-1984-0096, The University of Queensland)
Ano2023
Volume122
Páginas104210
Data de publicação2023-12-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoInternational Journal of Drug Policy (JOURNAL)
Identificadores do periódicoISSN: 0955-3959 • E-ISSN: 1873-4758
EditoraElsevier BV (PUBLISHER)
DOI10.1016/j.drugpo.2023.104210
PMID37813082
OpenAlexW4387421674
IdiomaEN
Citações recebidas4
Referências citadas26

In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported to the Therapeutic Goods Administration, and discusses the barriers that remain for patients who wish to access medical cannabis. It assesses how well the Australian program has addressed the challenges of providing patients with easier access to medical cannabis while ensuring that high-quality products are used safely and effectively under medical guidance

Business · Cannabis · Government (linguistics · Medical cannabis · Political science · Psychiatry · Public relations · Quality (philosophy · Cannabis and Cannabinoid Research · Homelessness and Social Issues · Medicine · Prenatal Substance Exposure Effects